Literature DB >> 17534822

Long-term clinical outcomes and therapeutic benefits of triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy: a case study.

A Ueno1, H Enaida, Y Hata, T Hisatomi, T Nakamura, Y Mochizuki, T Sakamoto, T Ishibashi.   

Abstract

PURPOSE: To investigate intraoperative visibility and long-term clinical outcome following triamcinolone acetonide (TA)-assisted pars plana vitrectomy (PPV) for proliferative vitreoretinopathy (PVR).
METHODS: A retrospective interventional noncomparative clinical study was carried out on 21 eyes from 21 patients with more than grade C2 PVR, all of whom underwent TA-assisted PPV. Two of the specimens were observed with an electron microscope. After treatment, outcome measures, including changes in best-corrected visual acuity (BCVA), intraocular pressure (IOP) elevation, corneal pathology, and occurrence of endophthalmitis, were recorded. Patient follow-up time was >36 months (mean +/-standard deviation = 47.3 +/- 6.7 months).
RESULTS: TA improved the intraoperative visualization of the epiretinal membrane (ERM), allowing it to be easily removed together with the partially internal limiting membrane (ILM) using micro forceps. The excised tissue consisted of proliferative cells and an extracellular matrix underlying the ILM. After the operation, 71.4% of the eyes had improved BCVA. Three of the eyes showed sustained IOP elevation (14.3%); two of these cases were controlled by the administration of eyedrops, while the third required filtering surgery. In two cases, an absorption delay of the TA granule on the retinal surface was observed. One eye developed corneal stromal opacity. No other severe complications occurred during the observation period.
CONCLUSIONS: TA-assisted PPV offers improved visualization during the surgical management of PVR, and allows surgeons to excise the ERM safely and effectively without the risk of serious complications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17534822     DOI: 10.1177/112067210701700320

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  7 in total

1.  Pars plana vitrectomy with and without triamcinolone acetonide assistance in pseudophakic retinal detachment complicated with proliferative vitreoretinopathy.

Authors:  Nur Acar; Ziya Kapran; Tugrul Altan; Yaprak Banu Unver; Ercan Pasaoglu
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

2.  Toxicity profiles of subretinal indocyanine green, Brilliant Blue G, and triamcinolone acetonide: a comparative study.

Authors:  Rasmus Ejstrup; M la Cour; S Heegaard; J F Kiilgaard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-16       Impact factor: 3.117

3.  Use of triamcinolone during vitrectomy surgery to visualize membranes and vitreous.

Authors:  Steven M Couch; Sophie J Bakri
Journal:  Clin Ophthalmol       Date:  2008-12

Review 4.  Visualizing vitreous in vitrectomy by triamcinolone.

Authors:  Taiji Sakamoto; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-06-20       Impact factor: 3.117

5.  Characterization of Macrophage-Like Cells in Retinal Vein Occlusion Using En Face Optical Coherence Tomography.

Authors:  Yunkao Zeng; Xiongze Zhang; Lan Mi; Yuhong Gan; Yongyue Su; Miaoling Li; Ruijun Yang; Yining Zhang; Feng Wen
Journal:  Front Immunol       Date:  2022-03-03       Impact factor: 7.561

6.  One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy.

Authors:  Keita Yamakiri; Taiji Sakamoto; Yoshihiro Noda; Masaaki Nakahara; Nobuchika Ogino; Toshiaki Kubota; Mitsunobu Yokoyama; Mariko Furukawa; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-23       Impact factor: 3.117

7.  Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy.

Authors:  Jinglin Cui; Hong Chen; Hang Lu; Fangtian Dong; Dongmei Wei; Yan Jiao; Steve Charles; Weikuan Gu; Lin Wang
Journal:  J Ophthalmol       Date:  2018-06-25       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.